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2 COULTER ET ALand lymphoma (13%). Unexpectedly, neurodevelopmental delay
occurred in 19% of the cohort, suggesting a role for PI3Kd in
the central nervous system; consistent with this, PI3Kd is
broadly expressed in the developing murine central nervous
system. Thoracic imaging revealed high rates of mosaic
attenuation (90%) and bronchiectasis (60%). Increased IgM
levels (78%), IgG deficiency (43%), and CD4 lymphopenia
(84%) were significant immunologic features. No immunologic
marker reliably predicted clinical severity, which ranged from
asymptomatic to death in early childhood. The majority of
patients received immunoglobulin replacement and antibiotic
prophylaxis, and 5 patients underwent hematopoietic stem cell
transplantation. Five patients died from complications of APDS.
Conclusion: APDS is a combined immunodeficiency with
multiple clinical manifestations, many with incomplete
penetrance and others with variable expressivity. The severity of
complications in some patients supports consideration of
hematopoietic stem cell transplantation for severe childhood
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Activated phosphoinositide 3-kinase d syndrome (APDS) is an
autosomal dominant primary immunodeficiency caused by gain-
of-function (GOF) mutations in PIK3CD,1,2 which encodes the
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TABLE I. Clinical manifestations of APDS
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COULTER ET AL 3Frequency, n/totalAbbreviations used
studied (%)APDS: Activated phosphoinositide-3 kinase d syndromeInfectious complication
BALF: Bronchoalveolar lavage fluidRecurrent respiratory tract infections 51/53 (98)
CMV: CytomegalovirusPneumonia 39/46 (85)*
CNS: Central nervous systemBronchiectasis 32/53 (60)
CT: Computed tomographyChronic rhinosinusitis 24/53 (45)
GOF: Gain of functionRecurrent otitis media 26/53 (49)
HSCT: Hematopoietic stem cell transplantation(with permanent hearing loss) 4/53 (8)
HSV: Herpes simplex virusSevere or persistent herpesvirus infection 26/53 (49)
OR: Odds ratioEBV 14/53 (26)
PI3K: Phosphoinositide 3-kinaseCMV 8/53 (15)
PPV: Pneumococcal polysaccharide vaccineHSV and VZV 11/53 (21)
Tonsillitis
(with tonsillectomy)
15/53 (28)
7/53 (13)
Ocular infections 10/53 (19)
Noninfectious complication
Lymphadenopathy§ 34/53 (64)
Splenomegaly 31/53 (58)
Hepatomegaly 24/53 (45)
Autoimmune disease 22/53 (42)
Nodular mucosal lymphoid hyperplasia 17/53 (32)
Enteropathyk 13/53 (25)
Developmental delay 10/53 (19)
Lymphoma 7/53 (13)
Total studied 5 53 unless otherwise indicated.
VZV, Varicella zoster virus.
*N 5 46 because 7 patients had no chest radiology available.
Pneumonia was defined as at least 1 clinically and radiologically diagnosed
pneumonia episode.
Bronchiectasis diagnosed on thoracic CT imaging.
§Lymphadenopathy persistent for at least 3 months.
kNine of 13 patients with enteropathy had gastrointestinal nodular mucosal lymphoid
hyperplasia confirmed on endoscopy.Recently, we described 17 patients with a combined immuno-
deficiency disorder caused by the heterozygous PIK3CD GOF
mutation E1021K.1 Patients’ lymphocytes displayed increased
basal and poststimulation phosphatidylinositol 3,4,5-
trisphosphate and enhanced downstream Akt–mammalian/mech-
anistic target of rapamycin signaling. This disorder was named
APDS.1 Lucas et al2 independently reported 14 patients with a
similar disease caused by E1021K and 2 other activating muta-
tions in PIK3CD, designating it p110d-activating mutation
causing senescent T cells, lymphadenopathy, and immunodefi-
ciency (PASLI).2 To date, 4 heterozygous GOF PIK3CD muta-
tions (E1021K, N334K, E525K, and C416R) have been
described, with E1021K the most common.1,2,6-8 Patients in
both cohorts experienced recurrent respiratory tract infections,
bronchiectasis, herpesvirus infections, nonneoplastic lymphopro-
liferation, and lymphoma. However, possibly because of different
case-finding strategies, we reported bronchiectasis in 75% of our
cohort and herpesvirus infections in 24%, whereas Lucas et al2
described bronchiectasis in 33%, but all patients had herpesvirus
viremia. Recent reports have also underscored that patients with
APDS have a high incidence of lymphoma7,8 and possible auto-
immune manifestations.2,9
In this study we describe the clinical, radiologic, histopatho-
logic, and immunologic features of APDS in a genetically
confirmed cohort of 53 patients, the largest to date. We
demonstrated a wide spectrum of clinical findings and complica-
tions and unexpectedly noted an increased frequency of neuro-
developmental manifestations. These findings will aid clinical
decision making in the diagnosis and treatment of APDS and
facilitate patient counseling.METHODS
Informed consent was obtained from patients, parents, or both. The study
conformed to the Declaration of Helsinki and all local ethical requirements.
Mutations in PIK3CD were identified by means of Sanger sequencing.1
Only patients heterozygous for an APDS-associated GOF PIK3CD mutation
were included. Twenty-five patients from this cohort have been included in
previous reports,1,7 and 28 are reported for the first time.
Information on demographics, presentation, complications, laboratory
parameters, management, and outcomes was compiled retrospectively by
using patient/parent interview and medical note review. Pneumonia and
bronchiectasis required radiologic confirmation. Chest computed tomo-
graphic (CT) scans from 31 patients were independently reviewed by 2
thoracic radiologists (J.B. and N.S.) for air-space opacity, atelectasis, nodules,
bronchiectasis, mosaic attenuation, and lymphadenopathy.10,11 Available his-
topathology specimens (29 specimens from 11 patients) were reviewed by 2
hematopathologists (C.M.B. and J.R.G.). Patients’ most recent immunologyresults are described; postrituximab B-cell levels were excluded. All labora-
tory results were analyzed with reference to age-related normal ranges.12-15
A poor pneumococcal polysaccharide vaccine (PPV) response was defined
as a less than 4-fold increase in antipneumococcal IgG titer at 4 to 6 weeks af-
ter PPV vaccination.
Significant associations in clinical complications were determined by odds
ratios (ORs) with 95% CIs and Fisher exact tests by using GraphPad Prism
software (version 6; GraphPad Software, La Jolla, Calif). P values of less than
.05 were considered significant.RESULTS
Patients’ characteristics
Fifty-three patients with APDS (34 male patients) from 30
unrelated families were included; 5 patients (4 male) were
deceased. Living patients had a mean age of 17.2 years (age
range, <1-65 years). Forty-two patients were of European
descent, 4 were Afro-Caribbean, 3 were Middle Eastern, 2 were
Indian, 1 was Chinese, and 1 was Japanese. Fifty patients were
heterozygous for E1021K, and 3 related subjects were heterozy-
gous for E525K.Presentation
Recurrent respiratory tract infections occurred in 96% of
patients, with onset from less than 1 to 7 years of age.
Lymphadenopathy, hepatosplenomegaly, or both were common
FIG 1. BCG-induced granulomatous inflammation in patients with APDS. 1,
Granulomatous skin lesion in a 4-year-old at the site of BCG vaccination
administered at 4 months of age. 2, Skin biopsy specimen showing granu-
lomatous inflammation.
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after their child received a diagnosis of APDS; 2 had bronchiec-
tasis and recurrent respiratory tract infections, 1 experienced
recurrent respiratory tract infections in childhood and a persistent
granulomatous local skin reaction to BCG vaccination, 1 was
under investigation for chronic cervical lymphadenopathy, and 1
had no reported health issues. The 4 symptomatic adults had
abnormal immunoglobulin profiles, including increased IgM and
reduced IgG2 levels, although none had a low total IgG level.Infective complications
Pneumonia (85%), bronchiectasis (60%), and upper respira-
tory tract infections were common, often with childhood onset
(Table I). Only 2 patients did not report recurrent respiratory
tract infections. The most common bacterial pathogens were
Streptococcus pneumoniae and Haemophilus influenzae, with
Staphylococcus aureus, Moraxella catarrhalis, Pseudomonas
aeruginosa, and Klebsiella species also observed. The mean
age at diagnosis of bronchiectasis was 8.6 years (range, 1.3-
36 years). Four patients had permanent hearing loss from recur-
rent otitis media. Non–respiratory tract bacterial infections
included ocular infections (21%: conjunctivitis [n 5 8], dacryo-
cystitis [n 5 3], and orbital cellulitis [n 5 2]) and abscesses
(17%: S aureus skin abscesses [n 5 4], salivary gland abscesses
[n 5 3], dental abscesses [n 5 3], and S pneumoniae lymph
node abscess [n 5 1]). No invasive bacterial infections were re-
ported. Two unrelated patients had persistent granulomatous
skin lesions at BCG vaccination injection sites (Fig 1); material
from 1 lesion was culture positive for BCG. No other mycobac-
terial infections were reported.
Persistent, severe, or recurrent herpesvirus infections
occurred in 49% of patients. EBV viremia was detected in
26%, with 6 (11%) patients having disseminated infection,
including 1 case of EBV encephalitis. EBV was detected in
lymph node (n 5 3), tonsillar (n 5 1), palatal (n 5 1), and
gastrointestinal (n 5 1) biopsy specimens, as well as cerebro-
spinal fluid (n 5 1) and bronchoalveolar lavage fluid (BALF;n 5 1). Two patients had EBV-positive lymphoma. Eight
patients had cytomegalovirus (CMV) viremia, 4 with systemic
CMV infection successfully treated with ganciclovir. Four cases
of EBV/CMV coinfection occurred. One patient with diffuse
lymphadenopathy and hepatosplenomegaly had EBV, CMV, and
human herpesvirus 6 identified by using PCR on lymph node
biopsy. Two patients were hospitalized with severe primary
varicella zoster virus infection, and 2 had recurrent shingles.
A nongenotyped sibling reportedly died of varicella zoster virus
pneumonitis at age 11 years. Recurrent herpes simplex virus
(HSV) infections included oral ulceration (n 5 4), skin
infections (n 5 2), and herpetic keratitis (n 5 1). HSV was
identified in BALF of 2 symptomatic patients, 1 with severe
pneumonitis. Adenovirus infections were reported in 9 (17%)
patients, with positive isolates from blood, BALF, and stool.
Warts (n 5 4) and Molluscum contangiosum (n 5 4) were
extensive in those affected.
Cryptosporidium parvum was isolated from a patient with
bloody diarrhea at age 6 to 18months in whom cirrhosis was iden-
tified at age 8 years; the liver biopsy specimen was negative for
Cryptosporidium species. A second patient had C parvum-posi-
tive diarrhea immediately after hematopoietic stem cell transplan-
tation (HSCT). The only other parasitic infection identified was
toxoplasmosis in a 9-month-old child. Oral mucocutaneous
candidiasis requiring treatment was reported in 7 (13%)
patients, including candida tracheitis (n 5 1) and esophageal
candidiasis (n 5 1). No cases of Aspergillus species infection
were identified.Noninfective immune complications
Nonneoplastic lymphoproliferation. Chronic lymphade-
nopathy, splenomegaly, and/or hepatomegaly were observed in
75% of patients (Table I). Lymphadenopathy typically began in
childhood, was persistent or recurrent, and was often localized
to sites of infection. There were 14 cases of cervical lymphade-
nopathy; 8 of 10 patients with persistent intrathoracic lymphade-
nopathy had bronchiectasis and recurrent consolidation. Seven
patients had diffuse lymphadenopathy, and EBV, CMV, or dual
viremia was diagnosed in all 6 of these patients in whom viral
PCR was performed. Lymphadenopathy was significantly associ-
ated with mucosal lymphoid hyperplasia (OR, 16; 95% CI, 1.9-
133.8; P 5 .002), splenomegaly (OR, 9.1; 95% CI, 2.5-33.2;
P 5 .0005), and herpesvirus infection (OR, 6.9; 95% CI, 1.9-
25.2; P 5 .004).
Histologically (Fig 2), lymph nodes showed atypical follicular
hyperplasia with absent or attenuated follicular mantle zones.
Germinal centers were frequently disrupted and partially effaced
by numerous T cells, many of which were programmed cell death
protein 1 (PD1)1, CD571, or both, which is consistent with follic-
ularTH cells. Parasinusoidal aggregates ofmonocytoidB cellswere
a recurrent feature. IgG1 plasmacellswere reduced in number.One
lymph node showed features analogous to those of posttransplanta-
tion lymphoproliferative disorder, which is characterized by a poly-
morphic infiltrate of B cells, T cells, epithelioid macrophages, and
light chain–restricted plasma cells; monocytoid B-cell hyperplasia;
and equivocal immunoglobulin gene rearrangement assays. There
was no progression to lymphoma on prolonged follow-up. Scat-
tered EBV-positive cells, CMV-positive cells, or both were present
in several lymph nodes, but florid infectious mononucleosis-like
pathology was not encountered. Mucosal nodular lymphoid
FIG 2. Lymphoid hyperplasia. 1 and 2, Lymph node showing atypical follicular hyperplasia with disrupted
follicles (arrows) andmonocytoid B cells (arrowheads). 3-5, Disrupted germinal centers were highlighted by
staining for CD20 (Fig 2, 3 and 4) and Bcl6 (Fig 2, 5). 6 and 7, Follicles were infiltrated by T cells (Fig 2, 6),
many of which expressed PD1, CD57, or both (Fig 2, 7). 8, IgM-positive plasma cells were present, but
IgG-positive plasma cells were reduced or absent. 9, Several lymph nodes contained CMV or EBV
(EBER). 10, Tracheal endoscopy showing mucosal nodules. 11 and 12, Lung showing peribronchiolar
lymphoid hyperplasia (Fig 2, 11) with disrupted follicles (Fig 2, 12). H&E, Hematoxylin and eosin.
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17 (32%) patients. In the gastrointestinal tract mucosal lymphoid
hyperplasia was identified endoscopically anywhere from the
epiglottis to the rectum in 14 (26%) subjects and associated with
diarrhea, bleeding, and rectal prolapse. Five patients had respira-
tory mucosal nodular lymphoid hyperplasia identified broncho-
scopically (Fig 2). Biopsy specimens from mucosal lymphoid
lesions showed follicular hyperplasia, often with features similarto those seen in lymph nodes (Fig 2), and were occasionally PCR
positive for herpes viruses (EBV, n5 1; HSV, n5 1).
Autoimmune and inflammatory disease. Thirty-four
percent of the cohort had clinical features suggestive of autoim-
mune or inflammatory disease. Cytopenias included Coombs-
positive hemolytic anemia (n 5 7) and 2 cases of trilineage
cytopenia responsive to steroids or rituximab. Glomerulonephritis
affected 3 children, necessitating renal transplantation in 2 cases.
FIG 3. p110d expression in the mouse brain. Brain sections of adult wild-
type (2lacZ cassette) mice (1) and p110 d kinase dead (1lacZ cassette) b-gal
reporter mice16 (2) stained with the neuronal stain cresyl violet (purple) and
X-gal (blue) representing p110d expression. Strong expression of p110d
was observed in areas of the hippocampus, cerebral cortex, and thalamus.
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ferative, and focal and segmental changes. Two patients had
exocrine pancreatic insufficiency. Autoantibody-positive thyroid
disease was diagnosed in 3 patients in adulthood. Two patients
had seronegative arthritis, and 1 had recurrent pericarditis.
Three patients had cirrhosis, of whom 1 also had sclerosing
cholangitis in the setting of previous Cryptosporidium species–
related diarrhea. Sclerosing cholangitis additionally affected a
second noncirrhotic patient who had no evidence of Cryptospo-
ridium species infection.9 Thirteen (25%) patients had chronic
diarrhea, 9 of whom had gastrointestinal nodular mucosal
lymphoid hyperplasia confirmed on endoscopy.
Lymphoma and other malignancy. Seven (13%) patients
had lymphoma at age 18months to 27 years. Therewere 2 cases of
diffuse large B-cell lymphoma, 1 EBV positive (see Fig E1 in this
article’s Online Repository at www.jacionline.org) and 1 EBV
negative.7 Single patients were reported as having nodular scle-
rosis classical Hodgkin lymphoma,7 nodal marginal zone lym-
phoma,1 and a lymphoplasmacytic lymphoma, the EBV status
of which were unknown. An EBV-positive Hodgkin-type lym-
phoproliferative disorder was diagnosed in a child after renal
transplantation. One child had a primary cutaneous anaplasticlarge cell lymphoma carrying t(6; 7) (p25; q23). This regressed
from a 93 6–cm mass of tumor nodules to a 53 4–cm diameter
flat erythematous plaque on 6 weeks of treatment with rapamycin
(sirolimus, see Fig E2 in this article’s Online Repository at www.
jacionline.org). Three patients died of lymphoma-related compli-
cations, including both patients with EBV-associated lymphoma.
No other malignancies have been identified within our cohort to
date.
Neurological and other nonimmune features. Global
developmental or isolated speech delay were diagnosed against
standard criteria by specialist pediatric services in 10 (19%)
patients. Three further patients were treated for anxiety disorders,
1 with a diagnosis of autism, and 3 children were reviewed by
psychological services for behavioral issues. Of note, PI3Kd is
strongly expressed in the mature and developing murine central
nervous system (CNS; Fig 3).16
Individual patients were born with macrocrania, unilateral
hypoplastic kidney, and unilateral microphthalmia.Thoracic radiology
Air-space opacity (Fig 4.1) was identified in 13 of 31 CT scans
reviewed, and tree-in-bud opacities, bronchial wall thickening, or
both were identified in 20 of 31 CT scans. Mosaic attenuation was
present in 28 of 31 patients and classified as mild in 17, moderate
in 7, and severe in 4 (Fig 4.2). Bronchiectasis was present in 21 of
31 scans, with an average of 3 lobes affected, and associated with
atelectasis or lobar collapse in 12 patients. Sixteen patients had
mediastinal lymphadenopathy, which was in a regional draining
station to concurrent lobar consolidation in 4 instances. Follow-
up imaging was available in 8 patients at a mean interval of
2.2 years. Four of the patients with air-space opacity, and regional
lymphadenopathy showed resolution of presumed pneumonic
changes but persistent volume loss, atelectasis, and development
of bronchiectasis (Fig 4.1).Immunology laboratory results
Lymphocyte immunophenotyping findings are summarized in
Table II. Typical findings were reduced CD4 T-cell counts,
increased CD8 T-cell counts of an effector/effector memory
phenotype, and an expansion of transitional B cells. A history
of herpesvirus infection was not associated with a deficiency in
natural killer cells (P 5 .48), TH cells (P 5 .47), or cytotoxic
T cells (P 5 .35). Serial B-cell counts (n 5 19) suggest that pa-
tients’ B-cell levels decrease more quickly over time than in
age-matched control subjects (Fig 5).
Immunoglobulin levels (Table III) were variable, with 43% of
patients having reduced total IgG levels. Fifty-eight percent of pa-
tients with normal IgG levels had IgG2 subclass deficiency, and
89% who underwent testing exhibited a poor response to PPV.
Reduced IgA (50%) and increased IgM (79%) levels were com-
mon. Two patients initially had marginally reduced IgM levels
(age, 2 and 6 years), which over time became high (27 g/L) or
normal (0.63 g/L), respectively. In 4 cases high IgM levels
normalized after commencement of immunoglobulin replace-
ment. One patient had a low IgG level after previous normal read-
ings. Four patients with normal IgG and IgA levels responded
poorly to PPV and had a previous diagnosis of specific antibody
deficiency.17
FIG 4. Radiology of patients with APDS. 1, CT scan of the chest (2-year-old boy), demonstrating right para-
tracheal lymphadenopathy (A), right upper lobe consolidation, and centrilobular nodules (B), progressing
2 years later to severe right upper lobe bronchiectasis (C). 2, CT scan of the chest (A-C) in a 7-year-old
boy reveals widespread mosaic attenuation (indicative of small airways disease), mild right upper lobe
bronchiectasis (A) and atelectasis (B, black arrows). 3, CT scan of the chest (A), abdomen (B), and pelvis
(C) of an 8-year-old boy showing axillary, paratracheal, para-aortic (black arrow), mesenteric and inguinal
lymphadenopathy (white arrows), and splenomegaly.
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Anti-infection prophylaxis. Sixty-two percent of the
cohort currently receive and an additional 9% previously received
antibiotic prophylaxis. Six (11%) patients are taking antiviral and
3 (6%) are taking antifungal prophylaxis.
Immunoglobulin replacement. Long-term immunoglob-
ulin replacement was administered to 87% of the cohort, with
reported benefit (reduction of infection) in themajority. In 3 patients
aged 14 to 23 years, immunoglobulin replacement was switched to
antibiotic prophylaxis (patient preference). The 7 patients who did
not receive immunoglobulin replacement therapy included the 5
patients identified by genotyping relatives of patients with APDS.
HSCT. Five (9%) patients aged 5 to 14 years have undergone
HSCT with medium- or reduced-intensity conditioning with a
median follow-up after HSCT of 4.2 years (range, 1-14 years).
Three transplantations (unrelated donors, one with 1A and 1B
allelic mismatch) were successful, with minimal graft-versus-
host disease, restoration of normal growth, and resolution of
infection and nonneoplastic lymphoproliferation; chimerism in
these patients ranged from 35% to 100%. A fourth procedure was
complicated by poor engraftment (25% donor chimerism),resulting in long-term immunoglobulin therapy after transplan-
tation. A fifth patient, who underwent splenectomy before
transplantation, died of sepsis 2 years after HSCT.
Immunosuppression. Thirty percent of the cohort under-
went at least 1 course of immunosuppressive therapy for lympho-
proliferative, autoimmune, or inflammatory disease. Rituximab
was of benefit in the management of autoimmune hemolytic
anemia (n 5 8) and nonneoplastic lymphoproliferation (n 5 5)
although often complicated by sustained B-cell lymphopenia. Six
patients were treated with rapamycin; 5 experienced benefit, with a
decrease in nonneoplastic or neoplastic lymphoproliferation, but
therapy was stopped in the fifth patient because of side effects.Fatal outcomes
Five patients with APDS died, 3 (aged 1, 19, and 27 years) from
lymphoma, 1 (aged 14 years) from sepsis after splenectomy and
HSCT, and 1 (aged 39 years) from respiratory failure and chronic
lung infection. Additionally, infection-related deaths in childhood
and early adult life (<_30 years old) were reported for 5 non-
genotyped relatives of patients with APDS.
TABLE II. Summary of lymphocyte phenotypic characteristics
of APDS
Lymphocyte subpopulation*
Frequency, n/total
studied (%)
T cells
Reduced TH cell counts (CD3
1CD41) 43/51 (84)
Reduced recent thymic emigrant T-cell counts
(CD31CD41CD45RA1CD311)
14/22 (64)
Normal cytotoxic T-cell counts (CD31CD81) 34/51 (67)
Reduced cytotoxic T-cell counts (CD31CD81) 14/51 (27)
Increased effector-effector memory cytotoxic T-
cell counts (CD31CD81CCR72CD45RA1/2)
17/18 (94)
Reversed CD4/CD8 ratio 33/51 (65)
B cells
Reduced B-cell counts (CD191) 32/48 (67)
Increased transitional B-cell counts
(CD191IgM11CD3811)
24/32 (75)
Reduced nonswitched memory B cells
(CD191IgD1CD271)
15/30 (50)
Reduced class-switched memory B-cell counts
(CD191IgD2CD271)
17/30 (57)
NK cells
Normal NK cell counts (CD161CD561) 28/43 (65)
Reduced NK cell counts (CD161CD561) 12/43 (28)
NK, Natural killer.
*Results were deemed reduced, normal, or increased with reference to age-related
normal ranges.12-14 Most recent results available were used, and B-cell levels after
rituximab were excluded.
FIG 5. Age-related changes in B-cell counts in patients with APDS. Age-
related median B-cell count (white dots), B-cell count 5th to 95th percentile
normal range (checked area), and less than 5th percentile normal B-cell
count (spotted area) were plotted.12
TABLE III. Summary of immunoglobulin characteristics of the
APDS cohort
Reduced,
n/total (%)
Normal,
n/total (%)
Increased,
n/total (%)
IgG 21/49 (43) 26/49 (53) 2/49 (4)
IgA 25/50 (50) 24/50 (48) 1/50 (0.5)
IgM 0/50 (0) 12/50 (24) 38/50 (76)
Pneumococcal
vaccine response*
25/28 (89) 3/28 (11)
Immunoglobulin results were deemed reduced, normal, or increased with reference to
age-related normal ranges.15
*A poor pneumococcal polysaccharide vaccine response was defined as less than 4-
fold increase in anti-pneumococcal IgG titer at 4 to 6 weeks after PPV vaccination. Of
the 25 patients in whom pneumococcal responses were not available, 15 had reduced
IgG levels and received immunoglobulin replacement therapy.
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We present an overview of the clinical course of APDS in the
largest cohort to date with confirmed GOF PIK3CD mutations.
The phenotype is highly variable (Fig 6), ranging from asymp-
tomatic adults to profound immunodeficiency causing early death
or necessitating HSCT in childhood; the clinical features overlap
those of other primary immunodeficiencies, such as cytotoxic T
lymphocyte–associated antigen 4 (CTLA4) and LPS-responsive
beige-like anchor protein (LRBA) deficiency. Interestingly, 3
recent publications18-20 describe heterozygous mutations in the
PIK3R1 gene (encoding the PI3K regulatory subunit), leading
to hyperactivation of PI3Kd and a clinical syndrome (APDS2 or
PASLI-R1) highly reminiscent of that described herein.
Conversely, a recessive mutation in PIK3R1, resulting in loss of
p85a expression, was reported in a patient with agammaglobulin-
emia and absent B-cell lineage.21 Together with the aberrant
lymphocyte function in mice lacking PI3Kd activity,22 these find-
ings indicate that balanced signaling in the PI3Kd pathway is crit-
ical for normal immune function.
Recurrent respiratory tract infection is almost universally
found in patients with APDS. Bacterial isolates were typical for
antibody deficiency, and the incidence of bronchiectasis was
similar or higher than in previously described common variable
immune deficiency cohorts (see Table E1 in this article’s Online
Repository at www.jacionline.org).23-26 Notably, 63% (20/32)
of patients with bronchiectasis had normal total IgG levels, sug-
gesting that patients with early-onset bronchiectasis and even mi-
nor immunoglobulin abnormalities should be screened for APDS
mutations. Increased IgM levels were seen in 82% of the cohort,
reminiscent of a class-switch recombination defect.7,8 Thus we
propose that patients presenting with reduced IgG and IgA levels
and normal or increased IgM levels,17 particularly those withnormal CD40 ligand expression, should be screened for activating
PI3Kd mutations.
Almost half of our cohort had difficulty in resolving herpes-
virus infections, particularly EBV and CMV. There was no
association between herpesvirus infections and decreased TH,
cytotoxic T-cell, or natural killer cell counts, suggesting a func-
tional defect underlies this susceptibility. Diffuse lymphadenopa-
thy was associated with systemic herpes infections, with
consistent features on lymph node histology. Other opportunistic
infections were uncommon, and patients did not experiencePneu-
mocystis jirovecii pneumonia.Cryptosporidium species was iden-
tified in only 2 cases, one of whom had cholangitis and liver
disease, which is normally associated with MHC class II or IL-
21/IL-21 receptor deficiencies but also described in CD40 ligand
and CD40 deficiency.27 Persistent granulomatous skin lesions af-
ter BCGvaccination occurred in 2 patients, but no othermycobac-
terial infections were reported. Although there was a moderate
excess of skin infections and abscesses, there were no cases of
invasive staphylococcal or Aspergillus species infections to sug-
gest major neutrophil dysfunction.
Although APDS can present as a common variable immune
deficiency–like disease, it is also characterized by viral in-
fections; lymphocyte immunophenotyping confirms APDS is a
combined immunodeficiency. The typical T-cell profile was of
reduced TH cells and recent thymic emigrants, whereas cytotoxic
T cells had a predominantly effector or activated phenotype.
FIG 6. Variation in clinical phenotypes of APDS. Each column represents a patient with APDS. Each row rep-
resents a frequent or serious complication of APDS.White boxes and gray boxes depict the absence or pres-
ence of a complication, respectively.
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time. The reduction in B-cell counts, including class-switched
memory B cells and expansion of transitional B cells, suggests
defects in B-cell maturation or enhanced mature B-cell death.22
The development of focal bronchiectasis observed after con-
solidative changes strengthens the suspected causal link between
infection and airway damage. Consistent with a role for infection
in the florid nonneoplastic lymphoproliferation characteristic of
patients with APDS, lymphadenopathy was often associated with
regional (mediastinal lymphadenopathy in bronchiectatic pa-
tients) or systemic infection (herpesviral infections) and tended
to improve on infection resolution. Our review of chest CT scans
also revealed an unexpectedly high incidence (28/31) of mosaic
attenuation, which is indicative of reduced perfusion of poorly
ventilated lung regions. This might reflect inflammatory small-
airway disease or result from viral respiratory tract infections.
Patients with APDS had a high incidence (34%) andwide range
of inflammatory/autoimmune manifestations. Enhanced PI3Kd
activity has been reported in patients with autoimmune diseases,
such as systemic lupus erythematosus,28 and PI3Kd modulates
regulatory T-cell function.29 Our findings suggest a role for
PI3Kd in the genesis or perpetuation of autoimmunity and poten-
tially for PI3Kd inhibition in treating such conditions. Activating
somatic PIK3CD mutations have been associated with lymphoid
malignancy.30 We identified 7 lymphomas in this series of 53 pa-
tients with a spectrum of pathologic subtypes but identified no
solid malignancies, perhaps reflecting the young age of our cohort
or the predominant expression of p110d in leukocytes. Although
PI3Kd is described as leukocyte restricted, expression is also
found in cells of breast or melanocytic origin,31 lung fibroblasts,32
and TNF-a–stimulated endothelial and synovial cells.33 p110d
has recently been shown to regulate epithelial cell polarity,34
which is of potential import for respiratory epithelial function.
It is tempting to speculate that induction of p110d expression
by locally produced TNF-a during inflammation might impair
epithelial barrier functions and aggravate local inflammation.
Thus the lung phenotype might be the result of interplay between
immune functions of p110d and epithelium-intrinsic roles of
p110d.
Almost one fifth of our cohort experienced neurodevelopmen-
tal morbidity, from speech delay to global developmental delay.
PI3Kd is expressed broadly in the developing CNS, as well as in
specific adult brain regions (including the hippocampus, cerebral
cortex, and thalamus) of reporter mice (Fig 3).16 PI3Kd has been
implicated in schizophrenia; pharmacologic inhibition reversedprepulse inhibition deficits in a rat model of schizophrenia and
blocked amphetamine-induced hyperlocomotion in a mouse
model of psychosis-like behavior.35 Interestingly, loss-off-
function phosphatase and tensin homolog (PTEN) mutations
(with consequent enhanced PI3K-dependent signaling) are asso-
ciated macrocrania and autism spectrum disorders.36 One patient
with APDS had macrocrania, and in addition to the single patient
with a formal diagnosis of autism in our cohort, before submission
of this manuscript, wewere informed of an additional patient with
APDS with autism spectrum disorder (personal communication;
Professor P. Martin von Hagen, Erasmus MC, The Netherlands).
These findings suggest PI3Kd might play an important but little-
understood role in the CNS, and this aspect of APDS warrants
further study.
HSCT has been seemingly curative in 3 patients with APDS
described herein and an additional 5 patients described by Imai
et al,37 supporting its use in carefully selected cases; however,
longer-term follow-up to determine the degree of donor chimerism
needed to achieve cure is required. Lucas et al2 reported a single pa-
tient in whom the mammalian/mechanistic target of rapamycin in-
hibitor rapamycin improved circulating T-cell profiles. Four
patients within our cohort experienced a decrease in nonneoplastic
lymphoproliferation while taking rapamycin, and this drug also led
to regression of cutaneous T-cell lymphoma. Nevertheless, direct
inhibition of activated PI3Kd might be a more attractive approach
in patients with APDS. Selective PI3Kd inhibitors are currently in
clinical trials for a range of cancers and inflammatory disorders, and
one compound is already approved for treatment of B-cell malig-
nancies.38,39 Such disease-specific therapy could address both the
infectious and noninfectious complications of APDS, but the re-
ported side effect profile and significant immunoparesis in mice
lacking PI3Kd function25 emphasize the need for careful dosing
to restore normal rather than abolish PI3Kd activity, particularly
given that long-term treatment is contemplated.
In conclusion, APDS is a combined immune deficiency with a
variable phenotype complicated by recurrent sinopulmonary
bacterial and herpesvirus infections, bronchiectasis, lymphoid
hyperplasia, autoimmunity, and, less frequently, neurodevelop-
mental delay and lymphoma. The rapidly increasing number of
patients identified since the initial description of APDS in 2013
suggests this is a clinically significant cause of primary immu-
nodeficiencies, which should be considered in patients presenting
with atypical or inherited primary antibody deficiency, bronchi-
ectasis, severe herpesvirus infections, and lymphoma. The
severity of complications and significant mortality rate support
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trials of selective PI3Kd inhibitors for this condition.
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Clinical implications: The variable clinical phenotype with se-
vere complications of bronchiectasis, bacterial and viral infec-
tions, and lymphoma suggests that patients who fit this
clinical profile should be screened for APDS-causing mutations.REFERENCES
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FIG E1. EBV-positive diffuse large B-cell lymphoma in patients with APDS. 1, A diffuse infiltrate of large
atypical lymphoid cells and some atypical plasmacytoid cells was present in the cerebellum. 2, Immunohis-
tochemical staining showed large B cells expressing CD20, CD79a, Pax5, and interferon regulatory factor 4
but not Bcl6 or CD10. 3, Most neoplastic cells showed positive in situ hybridization for EBV EBER. 4, Plas-
macytoid cells expressed CD138 and showed l restricted immunoglobulin light chain in situ hybridization.
H&E, Hematoxylin and eosin.
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FIG E2. Primary cutaneous anaplastic large cell lymphoma in patients with APDS. 1 and 2, A multinodular
cutaneous tumor on the chest of an 11-year-old boy (Fig E2, 1), which regressed to a flat plaque (Fig E2, 2) on
6 weeks of treatment with rapamycin. 3 and 4, The dermis and subcutis contained a diffuse infiltrate of large
atypical lymphoid cells. 5 and 6, Immunohistochemical staining showed large T cells expressing CD3 (Fig
E2, 5), CD30 (Fig E2, 6), CD2, interferon regulatory factor 4, T-cell receptor b, and perforin but not CD4,
CD8, or ALK. H&E, Hematoxylin and eosin.
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TABLE E1. Comparison of the frequency of complications in
patients with APDS and common variable immune deficiency
Clinical feature
Frequency (%)
in APDS cohort
Frequency (%)
in CVID cohort
Pneumonia 85 32-77E1-E4
Bronchiectasis 60 23-64E1,E3,E5-E7
Splenomegaly 58 15-30E1,E3-E6
Autoimmunity 42 22-29E1-E3
Enteropathy 25 9E1,E4,E5
Granuloma* 0 8-9E1,E2,E5
Meningitis/encephalitis 1.9 3-4E1,E4
Lymphoma 11 3-8E1,E2,E5
Living patients currently
receiving
immunoglobulin
replacement therapy
77 80E1
CVID, Common variable immune deficiency.
*Two patients with cutaneous granulomatous inflammation after BCG vaccination
were not included.
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